<DOC>
	<DOCNO>NCT00004727</DOCNO>
	<brief_summary>The African-American Antiplatelet Stroke Prevention Study design prevent recurrent stroke administration aspirin ticlopidine . The study also provide community information reduce risk stroke recognize symptom stroke . The study involve 50 participate hospital locate throughout United States . Study medication provide free charge , transportation stipend available need .</brief_summary>
	<brief_title>Antiplatelet Therapy Prevent Stroke African Americans</brief_title>
	<detailed_description>Stroke one important diseases disproportionately affect African-Americans . African-American men woman 2 time likely white die cerebrovascular disease experience stroke . Scientific information efficacy safety stroke preventative group much need , yet African-Americans minority underrepresented biomedical research study . Preliminary data collect nonwhite , predominantly African-American patient , suggest ticlopidine effective aspirin secondary prevention stroke death patient risk serious adverse event low . This multicenter , randomize , double-blind clinical trial ticlopidine hydrochloride ( 500mg/day ) aspirin ( 650mg/day ) African-American patient recent non-cardioembolic ischemic stroke . The primary purpose study compare efficacy ticlopidine aspirin prevention outcome endpoint recurrent stroke , vascular death , myocardial infarction African-American patient . Adverse experience study understanding safety medication group . The study conduct 50 site experience diagnosis treatment stroke . 1800 patient enrol 3-5 year , study least 2 year . Patients randomly assign treatment least 7 day , 90 day cerebral infarction . The trial promise provide much need information secondary stroke prevention African-Americans support establish African-American physician , church-based , community organization . Enrollment substantial number African-American woman anticipate . Data patient significantly add understand cerebrovascular disease among black woman . Furthermore , study could also serve organizational framework future study stroke prevention hyperacute treatment African-American population .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>African Americans eligible noncardioembolic ischemic stroke lease 7 day , 90 day enter trial . African American 2985 year age Noncardioembolic cerebral infarct Onset entry stroke least 7 day 90 day CT MRI follow entry stroke consistent occurrence entry stroke ( i.e. , show entry infarct , show old infarct , show infarct ) Measurable neurologic deficit correlate onset entry stroke . Informed consent Able follow outpatient treatment program Volunteers transient ischemic attack ( TIA ) potentially qualify event , intracranial hemorrhage , nonatherosclerotic stroke , sensitivity major allergy study drug , Modified Barthel Index &lt; 10 childbearing potential eligible . Nonqualifying entry event : TIA , subarachnoid hemorrhage , cardiac embolism , iatrogenic stroke , postoperative stroke within 30 day operation , carotid endarterectomy preventive treatment entry stroke . Mean arterial blood pressure &gt; 130mmHg 3 consecutive day Modified Barthel Index &lt; 10 History dementia neurodegenerative disease Severe comorbid condition cancer would limit survival 2 year followup period Concurrent enrollment another clinical trial Sensitivity allergy aspirin ticlopidine Women childbearing potential Peptic ulcer disease , active bleeding diathesis , low gastrointestinal bleeding , platelet hematologic abnormality currently active clinically active past year , hematuria , positive stool guaiac , prolong PT PTT , BUN &gt; 40mg % , serum creatinine &gt; 2.0mg % , thrombocytopenia neutropenia define low limit normal platelet count white blood cell count , respectively ( absolute neutrophil count &gt; 1800/mm3 required participation ) , &gt; 2 time upper range normal liver function test ( SGOT , SGPT , total bilirubin )</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>African American</keyword>
	<keyword>antiplatelet</keyword>
	<keyword>aspirin</keyword>
	<keyword>ASA</keyword>
	<keyword>acetylsalicylic acid</keyword>
	<keyword>ticlopidine</keyword>
	<keyword>prevention</keyword>
	<keyword>stroke</keyword>
	<keyword>cerebral infarction</keyword>
	<keyword>Chicago</keyword>
	<keyword>non-cardioembolic ischemic stroke</keyword>
</DOC>